Onsite
16 - 18 November 2024
European Society for Paediatric Endocrinology, 2024 (ESPE)
Presentation schedule and materials
Saturday, 16 November 2024
13:32
- 13:36
GMT
P1-68
POSTER
Impact of Idiopathic Short Stature (ISS) on children’s well-being
Anders Juul1,2,3; Agnes Linglart4; Michael Højby Rasmussen5; Tina Lund Leunbach5; Alberto Pietropoli6; Mikkel H Pedersen7; Lasse de Fries Jensen5
MATERIALS AVAILABLE
13:36
- 13:40
GMT
P1-58
POSTER
Somapacitan is effective and well tolerated in Chinese children with GHD: 52-week results from the randomized phase 3 REAL6 trial
Junfen Fu1; Xinran Cheng2; Michael Højby3; Chunxiu Gong4; Tina Lund Leunbach3; Yanhong Li5; Haiyan Wei6; Yu Zhu7; Yining Zhang8; Yan Zhong9 on behalf of the REAL6 study group
MATERIALS AVAILABLE
Sunday, 17 November 2024
00:00
- 00:00
GMT
P2-158
POSTER
Health care provider perspectives on Mallya Connectivity Cap & App for long-acting growth hormone in Slovenia
Primož Kotnik1,2; Klemen Dovč1,2; Barbara Murn Berkopec2; Liam McMorrow3; Tadej Battelino1,2
MATERIALS AVAILABLE
Monday, 18 November 2024
09:30
- 09:40
GMT
FC15.1
ORAL PRESENTATION
Response to daily and weekly recombinant human growth hormone treatment in children born small for gestational age is predicted more accurately by pre-treatment blood transcriptome than clinical variables
Terence Garner1; Philip Murray1,2; Michael Højby3; Ryan Anthony Ard3; Peter Clayton1,2; Adam Stevens1
MATERIALS AVAILABLE
10:20
- 10:30
GMT
FC15.6
ORAL PRESENTATION
Pharmacodynamic endpoints after once-weekly Somapacitan in children with GHD: 3-year results from REAL4 phase 3 study
Bradley S. Miller1; Joanne C. Blair2; Michael Højby Rasmussen3; Aristides Maniatis4; Jun Mori5; Volker Böttcher6; Ho-Seong Kim7; Michel Polak8; and Reiko Horikawa9
MATERIALS AVAILABLE
Keywords